Alentis Therapeutics, a leading biopharmaceutical company developing targeted treatments for cancer and fibrotic diseases, has secured $181.4 million in Series D funding round to develop targeted therapies for solid tumors.
The financing round was spearheaded by OrbiMed, Novo Holdings and Jeito Capital, with significant contributions from new investors Longitude Capital, Frazier Life Sciences, Catalio Capital, Avego Bioscience Capital, and Piper Heartland Healthcare Capital.
Existing investors RA Capital Management, Morningside Venture Investments, Bpifrance and BB Pureos, along with key institutional investors, participated in the round, boosting the company’s capital strength and valuation standing.
Led by Roberto Iacone, Dr. Luigi Manenti, Jon Freve, Rizwan Velji, Markus Meyer and Alberto Toso, the company aims to treat cancers and reverse fibrosis using anti-Claudin-1 monoclonal antibodies and antibody-drug conjugates (ADCs).
With the new financial backing, the company is looking to conduct Phase 1/2 clinical trials for its two first-in-class treatments targeting CLDN1, ALE.P02 and ALE.P03 and further a pipeline of successful candidates to commercialization.
As part of the investment deal, Dina Chaya (Partner at OrbiMed), Anna Chen (Principal at Frazier Life Sciences) and Brian Liu (Managing Director at Longitude Capital) will join Alentis Therapeutics board, bringing their vast experience and expertise to strengthen the company’s science, business and drug development.
